Shattuck Labs Reports Q1 2026 Financials, Reaffirms Cash Runway into 2029, and Advances Clinical Pipeline
STTK has more than doubled off its 52-week low of $0.712.
Summary
Shattuck Labs reported a Q1 2026 net loss of $14.8 million but reaffirmed its cash runway into 2029, while also announcing the completion of Phase 1 enrollment for SL-325 and plans for a Phase 2 trial.
Key Events · Earnings and Guidance · STTK
-
Q1 2026 Financial Results
Shattuck Labs reported a net loss of $14.8 million, or $0.13 per basic and diluted share, for the first quarter ended March 31, 2026, compared to a net loss of $13.7 million, or $0.27 per share, for the same period in 2025.
-
Cash Runway Reaffirmed
The company reported $90.4 million in cash and cash equivalents and investments as of March 31, 2026, and expects this to fund operations into 2029, assuming the full exercise of outstanding common stock warrants.
-
SL-325 Clinical Trial Progress
Enrollment for all cohorts in the Phase 1 clinical trial of SL-325 is complete, with data expected in the second quarter of 2026. Subject to positive Phase 1 data, a Phase 2 clinical trial in Crohn's disease is expected to initiate in the third quarter of 2026.
-
Bispecific Antibody Development
Shattuck's lead bispecific antibody has entered IND-enabling activities, with plans to disclose targets, preclinical data, and development timelines in the second quarter of 2026.
Analysis · STTK · Life Sciences
Shattuck Labs, a clinical-stage biotechnology company, reported a widened net loss for Q1 2026, but significantly, reaffirmed its cash runway into 2029, providing crucial financial stability for its ongoing clinical programs. The completion of Phase 1 enrollment for its lead candidate, SL-325, and the planned initiation of a Phase 2 trial in Crohn's disease are key milestones. Additionally, the advancement of a lead bispecific antibody into IND-enabling activities signals continued pipeline development. These clinical advancements, coupled with a strong cash position, are critical for investor confidence in a biotech company.
At the time of this filing, STTK was trading at $6.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $504.9M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.